Lunai Bioworks Inc. Cash and Restricted Cash
Lunai Bioworks Inc. (LNAI) had Cash and Restricted Cash of $3.16 million as of 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-05-15
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.16M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $491.64K.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $624.81K.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $92.70K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-03-31 | $3.16M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $491.64K 10-Q · filed 2026-02-17 |
| 2025-09-30 | $624.81K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $92.70K 10-Q · filed 2026-05-15 |
| 2025-03-31 | $923.00K 10-Q · filed 2026-05-15 |
| 2024-12-31 | $311.76K 10-Q · filed 2026-02-17 |
| 2024-09-30 | $220.57K 10-Q · filed 2025-11-14 |
| 2024-06-30 | $220.47K 10-Q · filed 2026-05-15 |
| 2024-03-31 | $312.70K 10-Q · filed 2025-05-15 |
| 2023-12-31 | $243.98K 10-Q · filed 2025-02-19 |
| 2023-09-30 | $523.47K 10-Q/A · filed 2025-02-19 |
| 2023-06-30 | $1.87M 10-K · filed 2025-09-29 |
| 2023-03-31 | $2.95M 10-Q/A · filed 2025-02-19 |
| 2022-12-31 | $4.12M 10-Q · filed 2024-02-14 |
| 2022-09-30 | $7.97M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $9.17M 10-Q/A · filed 2025-02-19 |
| 2022-03-31 | $11.15M 10-Q · filed 2022-05-13 |
| 2021-06-30 | $20.66M 10-K · filed 2023-10-02 |
| 2021-03-31 | $4.53M 10-Q · filed 2022-05-13 |
| 2020-06-30 | $8.70M 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |